RAB DIAGNOSTICS AS

Keywords

researchdevelopment workbiotechnologygenomicspharmageneticsgene samplesdna sequencingdna synthesisdna deepeninggenetic engineeringproteinsmoleculespeptide sequencinglipidglycotechniqueproteomicshormonesgrowth factorscell receptorspheromonescell culturetissue culturecrossingcell fusionvaccineimmunostimulatorsembryo manipulationprocess biotechnologybioreactorsfermentationbioprocessingbiorecoverybiodesulfurizationbiological pulp productionbiofiltrationbiological regenerationsubcellular organismsgene therapyvirusesvectors

Organization

CEO: AW
Anette Weyergang1979
Chairman of the board: ØA
Øyvind Kongstun Arnesen1957
Years since formation: 1 year; since Sep 15, 2023
Type: Limited company
VAT registered: No
Number of employees: 0

Ownership

Number of shares and share classes: 30,000; 1 share class
Total number of shareholders: 3; companies

Financials

Annual total result 2023: -2,670; NOK
Total equity 2023: 21,760; NOK

Last update: Aug 29, 2024

Management

Management / administration

Name	Role	Shares
AW Anette Weyergang 1979	Managing Director/CEO	50 % indirectly

Board

Name	Role	Shares
AK Alf Kristian Berg 1955	Board Member	25 % indirectly
ØA Øyvind Kongstun Arnesen 1957	Chairman	-
AM Anne Mathilde Henden Kvamme 1970	Board Member	-
EM Erling Magnus Hærem Sundrehagen 1951	Board Member	-
OJ Ole Jesper Dahlberg 1971	Board Member	-

Others

Name	Role	Shares
A ATHENE ACCOUNTING AS	Accountant	-

Top 10 individual shareholders

Name	Role	Shares
AW Anette Weyergang 1979	Managing Director/CEO	50 % indirectly
AK Alf Kristian Berg 1955	Board Member	25 % indirectly
OE Olav Engebråten 1964	-	25 % indirectly

Last update: Feb 23, 2024

Ownership

Company shareholders

Name	Share class	Number of shares	Share
I INNOWEYER AS	Ordinary shares	15,000	50 %
E ENGEFORSK INVEST AS	Ordinary shares	7,500	25 %
K KB LYSOVATE AS	Ordinary shares	7,500	25 %

Last update: May 24, 2024

Financials

in NOK

Summary

Year	2023
Total operating income	0
Annual Total Result	-2,670
Total assets	24,429
Total liabilities	2,669
Total equity	21,760

P&L

Year	2023
Total operating income	0
Total operating costs	2,670
Operating result	-2,670
Financial income/costs	0
Profit before tax	-2,670
Total tax & extraordinary income/cost	0
Annual Total Result	-2,670

Balance overview

Year	2023
Total fixed assets	0
Total current assets	24,429
Total assets	24,429
Short term debt	2,669
Long term debt	0
Total liabilities	2,669
Contributed capital	24,430
Retained earnings	-2,670
Total equity	21,760
Total equity and liabilities	24,429

RAB DIAGNOSTICS AS932 079 712